Application of IL-2 and other cytokines in renal cancer (Q35753505)

10 August 2017

1 reference

title

Application of IL-2 and other cytokines in renal cancer (English)

1 reference

10 August 2017

David F McDermott

1

1 reference

PubMed ID

15102596

10 August 2017

Michael B Atkins

series ordinal

2

1 reference

PubMed ID

15102596

10 August 2017

language of work or name

English

0 references

publication date

1 April 2004

1 reference

Expert Opinion on Biological Therapy

10 August 2017

1 reference

10 August 2017

4

1 reference

10 August 2017

4

1 reference

10 August 2017

455-468

1 reference

10 August 2017

Cancer statistics, 2003.

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.4.455

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.4.455

Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.4.455

Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. Canadian Urologic Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.4.455

Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.4.455

Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.4.455

Successful immunotherapy of natural killer-resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin 2

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.4.455

Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.4.455

Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma: an interim report

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.4.455

Treatment of advanced renal cell cancer with sequential intravenous recombinant interleukin-2 and subcutaneous alpha-interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.4.455

Subcutaneous interleukin-2 plus interferon alfa-2a in metastatic renal cancer: an outpatient multicenter trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.4.455

Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.4.455

Reduction of toxicity of interleukin-2 and lymphokine-activated killer cells in humans by the administration of corticosteroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.4.455

Granulocyte-macrophage--colony stimulating factor in metastatic renal cell carcinoma: a phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.4.455

Granulocyte-macrophage-colony stimulating factor in combination immunotherapy for patients with metastatic renal cell carcinoma: results of two phase II clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.4.455

Immune effects of escalating doses of granulocyte-macrophage colony-stimulating factor added to a fixed, low-dose, inpatient interleukin-2 regimen: a randomized phase I trial in patients with metastatic melanoma and renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.4.455

Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.4.455

Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.4.455

21 January 2018

Identifiers

DOI

10.1517/14712598.4.4.455

1 reference

10 August 2017

1 reference

PubMed ID

15102596